Neuland Laboratories to host analysts at Goldman Sachs CDMO day
- Neuland Laboratories to attend Goldman Sachs Global Healthcare CDMO Day
- Event scheduled for September 23-25, 2026 in Singapore
- Management to hold group and one-on-one investor meetings
- Disclosure made under SEBI Regulation 30 on September 16, 2026

*this image is generated using AI for illustrative purposes only.
Neuland Laboratories will participate in the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 23-25, 2026. The company's management team is scheduled to hold both group and one-on-one meetings with institutional investors and analysts during the event.
Meeting Details
The engagement forms part of Neuland's investor relations calendar for the quarter. The company disclosed the schedule under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
| Date | Event | Location | Format |
|---|---|---|---|
| September 23-25, 2026 | Goldman Sachs Global Healthcare CDMO Day | Singapore | Group and One-on-One |
Sarada Bhamidipati, Company Secretary, signed the intimation filed with the Bombay Stock Exchange and National Stock Exchange on September 16, 2026. The company noted that the schedule and participant list remain subject to change based on exigencies involving participants or the company.
Historical Stock Returns for Neuland Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.77% | -4.03% | -3.47% | +86.10% | +41.37% | +1,314.33% |
How might Neuland Laboratories' presentation at the Goldman Sachs CDMO Day influence its valuation multiples relative to global peers in the coming quarter?
What specific strategic initiatives or capacity expansion plans is Neuland likely to highlight to attract long-term institutional capital during these meetings?
Could increased engagement with global investors signal Neuland's intent to pursue cross-border M&A or joint ventures in the CDMO sector?


































